Lineage Cell Therapeutics, Inc. — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/63b98d78-c779-400f-adaa-b2212b90b69f/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-63.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-093992 |
| FY 2024 | $-18.6M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-036309 |
| FY 2023 | $-21.5M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-027988 |
| FY 2022 | $-26.3M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-007129 |
| FY 2021 | $-43.0M | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-006520 |
| FY 2020 | $-20.6M | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-005814 |
| FY 2019 | $-11.7M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-003818 |
| FY 2018 | $-46.0M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-003335 |
| FY 2017 | $-20.0M | 2017-01-01 – 2017-12-31 | evidence 0001493152-18-003416 |
| FY 2016 | $33.6M | 2016-01-01 – 2016-12-31 | evidence 0001140361-17-012402 |
| FY 2015 | $-47.0M | 2015-01-01 – 2015-12-31 | evidence 0001140361-16-057879 |
| FY 2014 | $-36.4M | 2014-01-01 – 2014-12-31 | evidence 0001140361-16-057879 |
| FY 2013 | $-43.9M | 2013-01-01 – 2013-12-31 | evidence 0001140361-16-057879 |
| FY 2012 | $-21.4M | 2012-01-01 – 2012-12-31 | evidence 0001140361-13-012991 |
| FY 2011 | $-16.5M | 2011-01-01 – 2011-12-31 | evidence 0001140361-12-015539 |
| FY 2010 | $-11.2M | 2010-01-01 – 2010-12-31 | evidence 0001140361-12-015539 |
| FY 2009 | $-5.1M | 2009-01-01 – 2009-12-31 | evidence 0001140361-12-015539 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Lineage Cell Therapeutics, Inc. — all facts · Revenue · Operating Income